title: NTPDase1 controls IL-8 production by human neutrophils.
abstract: The ectonucleotidase NTPDase1 (CD39) terminates P2 receptor activation by the hydrolysis of extracellular nucleotides (i.e., the P2 receptor ligands). In agreement with that role, exacerbated inflammation has been observed in NTPDase1-deficient mice. In this study, we extend these observations by showing that inhibition of NTPDase1 markedly increases IL-8 production by TLR-stimulated human neutrophils. First, immunolabeling of human blood neutrophils and neutrophil-like HL60 cells displayed the expression of NTPDase1 protein, which correlated with the hydrolysis of ATP at their surface. NTPDase1 inhibitors (e.g., NF279 and ARL 67156) as well as NTPDase1-specific small interfering RNAs markedly increased IL-8 production in neutrophils stimulated with LPS and Pam(3)CSK(4) (agonists of TLR4 and TLR1/2, respectively) but not with flagellin (TLR5) and gardiquimod (TLR7 and 8). This increase in IL-8 release was due to the synergy between TLRs and P2 receptors. Indeed, ATP was released from neutrophils constitutively and accumulated in the medium upon NTPDase1 inhibition by NF279. Likewise, both human blood neutrophils and neutrophil-like HL60 cells produced IL-8 in response to exogenous nucleotides, ATP being the most potent inducer. In agreement, P2Y(2) receptor knockdown in neutrophil-like HL60 cells markedly decreased LPS- and Pam(3)CSK(4)-induced IL-8 production. In line with these in vitro results, injection of LPS in the air pouches of NTPDase1-deficient mice triggered an increased production of the chemokines MIP-2 and keratinocyte-derived chemokine (i.e., the rodent counterparts of human IL-8) compared with that in wild-type mice. In summary, NTPDase1 controls IL-8 production by human neutrophils via the regulation of P2Y(2) activation.
authors.affiliation: Centre de Recherche en Rhumatologie et Immunologie, Centre Hospitalier Universitaire de Québec (pavillon Centre Hospitalier de l'Université Lava), Québec City, Québec G1V 4G2, Canada. Filip.Kukulski@crchul.ulaval.ca
authors.forename: Filip
authors.initials: F
authors.lastname: Kukulski
authors.forename: Fariborz
authors.initials: F
authors.lastname: Bahrami
authors.forename: Fethia
authors.initials: F
authors.lastname: Ben Yebdri
authors.forename: Joanna
authors.initials: J
authors.lastname: Lecka
authors.forename: Mireia
authors.initials: M
authors.lastname: Martín-Satué
authors.forename: Sébastien A
authors.initials: SA
authors.lastname: Lévesque
authors.forename: Jean
authors.initials: J
authors.lastname: Sévigny
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000096:biosynthesis / Q000502:physiology*; D001081:Apyrase / Q000096:biosynthesis / Q000172:deficiency / Q000502:physiology*; D002634:Chemotaxis, Leukocyte / Q000276:immunology; D005110:Extracellular Space / Q000201:enzymology / Q000276:immunology / Q000378:metabolism; D018922:HL-60 Cells; D006801:Humans; D016209:Interleukin-8 / Q000096:biosynthesis*; D008070:Lipopolysaccharides / Q000008:administration & dosage; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009504:Neutrophils / Q000201:enzymology* / Q000276:immunology* / Q000378:metabolism; D051193:Toll-Like Receptors / Q000502:physiology
chemical_list: D015703:Antigens, CD; C508606:CXCL8 protein, human; D016209:Interleukin-8; D008070:Lipopolysaccharides; D051193:Toll-Like Receptors; D001081:Apyrase; C067869:CD39 antigen